Cancer drug shows promise for rare salivary gland tumor
NCT ID NCT02098538
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase II trial tested the oral drug regorafenib in 38 patients with progressive, recurrent, or metastatic adenoid cystic carcinoma, a rare cancer of the salivary glands. Regorafenib works by blocking signals that help cancer cells grow and by cutting off blood supply to tumors. The study aimed to see if the drug could stop or slow the cancer's growth, with patients starting at a lower dose to reduce side effects. Results will help determine if regorafenib should be studied further for this hard-to-treat cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Regorafenib (a cancer drug that blocks tumor growth and blood vessel formation)
What this could lead to
If it works, this could provide a new treatment option for people with advanced adenoid cystic carcinoma, a rare cancer with few effective therapies.
What could go wrong
This is a small, early-phase trial with only 38 participants. The drug may not shrink tumors or slow progression, and side effects like fatigue, hand-foot skin reaction, and high blood pressure are common.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOID CYSTIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Memorial Sloan Kettering Cancer Center
Basking Ridge, New Jersey, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center @ Suffolk
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Westchester
Harrison, New York, 10604, United States
-
Memorial Sloan Kettering at Mercy Medical Center
Rockville Centre, New York, United States